Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers

被引:293
|
作者
Scheuer, L
Kauff, N
Robson, M
Kelly, B
Barakat, R
Satagopan, J
Ellis, N
Hensley, M
Boyd, J
Borgen, P
Norton, L
Offit, K
机构
[1] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast & Gynecol Serv, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2002.20.5.1260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. Patients and Methods: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardised questionnaires, chart reviews, and contact with primary physicians. Results: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopion tube neoplasm were found. Radiographic or tumor marker-based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing. Conclusion: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1260 / 1268
页数:9
相关论文
共 50 条
  • [41] Anxiety in BRCA mutation carriers: The impact of prophylactic breast surgery
    Butler, Elizabeth
    Kwait, Rebecca
    Laprise, Jessica
    Wilbur, Jennfer Scalia
    Spinette, Sarah
    Raker, Christina
    Gitierrez, Julia
    Legare, Robert
    Gass, Jennifer
    Stuckey, Ashley
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : 104 - 105
  • [42] Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance
    Niki J. Agnantis
    Evangelos Paraskevaidis
    Dimitrios Roukos
    Annals of Surgical Oncology, 2004, 11 : 1030 - 1034
  • [43] Preventing breast, ovarian cancer in BRCA carriers: Rational of prophylactic surgery and promises of surveillance
    Agnantis, NJ
    Paraskevaidis, E
    Roukos, D
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (12) : 1030 - 1034
  • [44] Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers (vol 149, pg 1306, 2014)
    Gangi, Alexandra
    Cass, Ilana
    Paik, Daniel
    JAMA SURGERY, 2015, 150 (02) : 183 - 183
  • [45] Ovarian carcinoma in BRCA mutation carriers
    Kenemans, Peter
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 33 - 33
  • [47] Value of Prophylactic Mastectomy in BRCA Mutation Carriers with Ovarian Cancer
    Gamble, C. R.
    Havrilesky, L.
    Hollenbeck, S.
    Myers, E.
    Greenup, R.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S61 - S61
  • [48] Comparison of Nodal Metastasis Between BRCA Mutation Carriers and Non-BRCA Mutation Carriers with Breast Cancer
    Shahrbanoo F. Noori
    Alexandra Gangi
    Maria E. Nelson
    Michael Choi
    Parisa Mirzadehgan
    Alison K. Bonk
    James Mirocha
    Farin Amersi
    Armando E. Giuliano
    Annals of Surgical Oncology, 2014, 21 : 3324 - 3329
  • [49] Comparison of Nodal Metastasis Between BRCA Mutation Carriers and Non-BRCA Mutation Carriers with Breast Cancer
    Noori, Shahrbanoo F.
    Gangi, Alexandra
    Nelson, Maria E.
    Choi, Michael
    Mirzadehgan, Parisa
    Bonk, Alison K.
    Mirocha, James
    Amersi, Farin
    Giuliano, Armando E.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (10) : 3324 - 3329
  • [50] Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review
    Huber, D.
    Seitz, S.
    Kast, K.
    Emons, G.
    Ortmann, O.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 301 (04) : 875 - 884